JP2017524013A5 - - Google Patents

Download PDF

Info

Publication number
JP2017524013A5
JP2017524013A5 JP2017507775A JP2017507775A JP2017524013A5 JP 2017524013 A5 JP2017524013 A5 JP 2017524013A5 JP 2017507775 A JP2017507775 A JP 2017507775A JP 2017507775 A JP2017507775 A JP 2017507775A JP 2017524013 A5 JP2017524013 A5 JP 2017524013A5
Authority
JP
Japan
Prior art keywords
alkyl
compound according
hydrogen
substituted
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017507775A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524013A (ja
JP6250226B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/068349 external-priority patent/WO2016023858A1/en
Publication of JP2017524013A publication Critical patent/JP2017524013A/ja
Publication of JP2017524013A5 publication Critical patent/JP2017524013A5/ja
Application granted granted Critical
Publication of JP6250226B2 publication Critical patent/JP6250226B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017507775A 2014-08-11 2015-08-10 Smac模倣薬としての6−アルキニル−ピリジン誘導体 Active JP6250226B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14180554 2014-08-11
EP14180554.9 2014-08-11
PCT/EP2015/068349 WO2016023858A1 (en) 2014-08-11 2015-08-10 6-alkynyl-pyridine derivatives as smac mimetics

Publications (3)

Publication Number Publication Date
JP2017524013A JP2017524013A (ja) 2017-08-24
JP2017524013A5 true JP2017524013A5 (en:Method) 2017-10-05
JP6250226B2 JP6250226B2 (ja) 2017-12-20

Family

ID=51300621

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017507775A Active JP6250226B2 (ja) 2014-08-11 2015-08-10 Smac模倣薬としての6−アルキニル−ピリジン誘導体

Country Status (34)

Country Link
US (4) US9481673B2 (en:Method)
EP (1) EP3180339B1 (en:Method)
JP (1) JP6250226B2 (en:Method)
KR (1) KR102445744B1 (en:Method)
CN (2) CN111440164B (en:Method)
AP (1) AP2017009718A0 (en:Method)
AR (1) AR101479A1 (en:Method)
AU (1) AU2015303308B2 (en:Method)
BR (1) BR112017002498B1 (en:Method)
CA (1) CA2956123C (en:Method)
CL (1) CL2017000326A1 (en:Method)
CO (1) CO2017001226A2 (en:Method)
CY (1) CY1121273T1 (en:Method)
DK (1) DK3180339T3 (en:Method)
EA (1) EA031424B1 (en:Method)
ES (1) ES2711763T3 (en:Method)
HR (1) HRP20190336T1 (en:Method)
HU (1) HUE043915T2 (en:Method)
IL (1) IL249844B (en:Method)
LT (1) LT3180339T (en:Method)
ME (1) ME03303B (en:Method)
MX (1) MX2017001835A (en:Method)
NZ (1) NZ728073A (en:Method)
PE (1) PE20170193A1 (en:Method)
PH (1) PH12017500231A1 (en:Method)
PL (1) PL3180339T3 (en:Method)
PT (1) PT3180339T (en:Method)
RS (1) RS58355B1 (en:Method)
SG (1) SG11201700999YA (en:Method)
SI (1) SI3180339T1 (en:Method)
TR (1) TR201902023T4 (en:Method)
TW (1) TWI723959B (en:Method)
UA (1) UA118887C2 (en:Method)
WO (1) WO2016023858A1 (en:Method)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR101479A1 (es) * 2014-08-11 2016-12-21 Boehringer Ingelheim Int Derivados de 6-alquinil-piridina
CN109153645B (zh) * 2016-05-19 2022-06-21 勃林格殷格翰国际有限公司 制备6-炔基-吡啶衍生物的方法
MA47106A (fr) 2016-12-21 2019-10-30 Amgen Inc Formulations d'anticorps anti-tnf alpha
JP2020515600A (ja) * 2017-03-31 2020-05-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗がん併用療法
CN113453678A (zh) 2018-11-26 2021-09-28 德彪药业国际股份公司 Hiv感染的联合治疗
TWI894135B (zh) 2019-01-25 2025-08-21 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒
JP2022550037A (ja) 2019-09-25 2022-11-30 デバイオファーム インターナショナル エス.エー. 局所進行性扁平上皮癌を有する患者の治療のための投与レジメン
WO2021245111A1 (en) 2020-06-03 2021-12-09 Boehringer Ingelheim International Gmbh Recombinant rhabdovirus encoding for a cd80 extracellular domain fc-fusion protein
WO2024175554A1 (en) 2023-02-21 2024-08-29 Institut Curie Trail agonists for use in the treatment of cancer in patients having an activating alteration of fgfr3

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060234360A1 (en) 2005-04-13 2006-10-19 Paola Branduardi Ascorbic acid production from D-glucose in yeast
US7989441B2 (en) 2005-06-08 2011-08-02 Novartis Ag Organic compounds
WO2007101347A1 (en) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
RU2009125620A (ru) 2006-12-07 2011-01-20 Новартис АГ (CH) Органические соединения
US8859541B2 (en) * 2012-02-27 2014-10-14 Boehringer Ingelheim International Gmbh 6-alkynylpyridines
US9278978B2 (en) 2013-08-23 2016-03-08 Boehringer Ingelheim International Gmbh 6-Alkynyl Pyridine
US9249151B2 (en) 2013-08-23 2016-02-02 Boehringer Ingelheim International Gmbh Bis-amido pyridines
AR101479A1 (es) * 2014-08-11 2016-12-21 Boehringer Ingelheim Int Derivados de 6-alquinil-piridina

Similar Documents

Publication Publication Date Title
JP2017524013A5 (en:Method)
JP2014193925A5 (en:Method)
JP2015508103A5 (en:Method)
RU2016141934A (ru) Ингибиторы циклин-зависимой киназы 7 (cdk7)
JP2016515561A5 (en:Method)
JP2017525730A5 (en:Method)
JP2016530259A5 (en:Method)
JP2019524883A5 (en:Method)
JP2019517487A5 (en:Method)
JP2015501833A5 (en:Method)
JP2013522292A5 (en:Method)
JP2016522266A5 (en:Method)
JP2015514806A5 (en:Method)
JP2012153722A5 (en:Method)
JP2018525441A5 (en:Method)
JP2016040288A5 (en:Method)
RU2015118135A (ru) Содержащие заместители бензольные соединения
JP2016503799A5 (en:Method)
JP2015512943A5 (en:Method)
JP2013502441A5 (en:Method)
JP2019528307A5 (en:Method)
JP2017501237A5 (en:Method)
JP2016531126A5 (en:Method)
JP2019500315A5 (en:Method)
JP2014510147A5 (en:Method)